Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
697 Burke Road
Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,702.15 | 0.20 | 0.00% |
| DAX 40 | 22,271.56 | 29.19 | -0.13% |
| Dow JONES (US) | 45,165.80 | 794.31 | -1.73% |
| FTSE 100 | 10,025.11 | 57.76 | 0.58% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,370.69 | 106.47 | -1.64% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |